Australia - engelsk - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - sea snake antivenom, quantity: 1000 u - injection, concentrated - excipient ingredients: phenol; sodium chloride; water for injections - for the treatment of patients who exhibit manifestations of systemic envenoming following a bite by a sea snake.

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - egg drop sydrome 76 virus strain bc 14; newcastle disease virus clone 30 - misc. vaccines or anti sera - egg drop sydrome 76 virus strain bc 14 vaccine-viral active 6.5 units; newcastle disease virus clone 30 vaccine-viral active 50.0 units - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - avian haemagglutinating adenovirus | newcastle disease | adenovirus | egg drop syndrome

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - inactivated gumboro virus; inactivated newcastle disease virus antigen - misc. vaccines or anti sera - inactivated gumboro virus biological-virus active 0.0 vnu/dose; inactivated newcastle disease virus antigen vaccine-viral active 0.0 hi/dose - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - infectious bursal disease | newcastle disease | bursal disease

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - inactivated newcastle disease virus antigen - misc. vaccines or anti sera - inactivated newcastle disease virus antigen vaccine-viral active 0.0 p - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - newcastle disease | vaccine | equine rotavirus

Romania - rumensk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

seacross pharma (europe) limited - irlanda - pemetrexedum - pulb. pt. conc. pt. sol. perf. - 100mg - antimetaboliti analogi ai acidului folic

Romania - rumensk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

seacross pharma (europe) limited - irlanda - pemetrexedum - pulb. pt. conc. pt. sol. perf. - 500mg - antimetaboliti analogi ai acidului folic

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sea snake antivenom -

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

united italian trading (m) sdn bhd - sea snake antivenom -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamotrigine, quantity: 200 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; povidone; saccharin sodium; purified talc; magnesium stearate; mannitol; flavour - seaze is an antiepileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as add-on therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy therapy in newly diagnosed paediatric patients is not recommended.( see pharmacology, clinical trials.)

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamotrigine, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; povidone; saccharin sodium; purified talc; magnesium stearate; mannitol; flavour - seaze is an antiepileptic drug for the treatment of partial and generalised seizures in adults and children. there is extensive experience with lamotrigine used initially as add-on therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy therapy in newly diagnosed paediatric patients is not recommended.( see pharmacology, clinical trials.)